Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

April 10, 2006 at 1:14 PM

Patent lifts Cell Therapeutics stock

Shares of Seattle biotechnology company Cell Therapeutics closed up 10.6 percent Monday after it announced a new patent.

The company patented CT-45099, which it described as the first agent from a new class of anti-cancer compounds to reach animal testing. The compound is a small-molecule antitubulin and differs from other cancer drugs in its method of action against tumor cells, the company said.

Patented through its European subsidiary, the drug may be effective against cancers that develop resistance to other chemotherapies.

Cell Therapeutics was up 19 cents to close at $1.98 this afternoon on heavier-than-normal volume.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►